Disclosure Information
|
|
- Ralph Sherman
- 5 years ago
- Views:
Transcription
1 Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population
2 Pediatric Depression & Anxiety The Art & the Science. Presenter Muhammad Junaid M.D Medical Director Child and Adolescent Partial Hospital Program North Shore University Health System. 10/01/2016
3 Learning Objectives At the conclusion of this activity the participant will be able to: Recognize major symptoms and risk factors of Pediatric Depression & Anxiety. Learn about different screening tools and Behavioral Checklists help to identify Pediatric Depression and Anxiety. Learn about evidence based treatment modalities.
4 Life time Prevalence of Depression National Co-morbidity Survey Adolescent Supplement. Face to Face study of 10,123 US adolescents, ages of 13 to 18 years. Modified version of WHO Composite International Diagnostic Interview Sex Age Total Severe impairme nt MDD or Dysthymia M % F % Merikangas KR et al,jaacap2010;49:
5 DSM V Criteria Sad mood Anhedonia Changes in appetite Psychomotor retardation Weight loss or gain Insomnia or hypersomnia Problems in concentration or indecisiveness Guilt Suicidal ideation or homicidal ideation
6 Screening for Adolescent Depression Comparison of Patient Health Questionnaire 9 item (PHQ-9) PHQ -A 9 items Interest or Pleasure Depressed Sleep Fatigue Appetite Psychomotor retardation Concentration. Suicidality PHQ-9 more valid Sensitivity 90% Specificity 87% Reynolds Depression Scale Good screening tool both for group settings and individual settings
7 Risk factors for Adolescent Depression History of concussion (3.3 fold increased risk) Parental job loss (2-3 % increased in suicide related behavior particularly in girls) Parental suicidal attempt (5 fold increased risk) Gassman-Pines et al Journal of Adolescent health 2014 Brent DA et al JAMA Psychiatry December 2014.
8 Major depression in Youth and Cardiovascular Disease American Heart Association Scientific Statement : Major depression in youth is a moderate risk condition for accelerated Atherosclerosis,& early Cardiovascular Disease Goldstein Bi Et al Circulation 2015
9 Depression and Disability Adjusted life years lost (DALY) Unipolar Depressive Disorders are the top most cause of DALY in Eastern Mediterranean, European, and Western Pacific regions World Health Organization
10 Top Ten Causes of Death Among Adolescents Road injury HIV/AIDS Suicide Lower respiratory infections Interpersonal violence Diarrheal diseases Drowning Meningitis Epilepsy Endocrine blood and immune disorders World Health Organization AAU Study Highlights NorthShore April 21, 2010
11 Prevalence of Suicidal Behavior Greater in Depressed Adolescents National Comorbidity Survey of 6483 adolescents Suicidal ideation: 12.1% Suicidal plans: 4.0% Suicide Attempt: 4.1% Nock MK et al Jama Psychiatry 2013:70:
12 Outcome of Adolescent Depression Outcome 3-9 years (mean 6 years) -93% full remission from index episode -53% recurrence of Depressive Disorder -79% Developed non-mood disorder (anxiety, substance use, eating disorders) -Only 15% had no subsequent depressive episode or other non-mood disorder Melvin GA et al J of Affective Disorders 2013,151:
13 FDA Approval for Acute Treatment of Major Depressive disorder Fluoxetine (three studies) ages 8-17 Escitalopram (one study) ages Emslie Gj et al J Am Academy of Child and Adolescent Psychiatry.
14 Other Controlled Pediatric Depression Trials Positive Studies Medication Ages Number of studies Citalopram 7-17 years 1 Sertraline 6-17 years 2 Wanger et al 2003, March et al 2004
15 Negative Studies Medication Ages Number of studies Citalopram Escitalopram Paroxetine Mirtazapine Nefazadone Venlafaxine March et al 2004, Wagneret et al 2003
16 Meta-Analysis of Antidepressants Trials in Youth Antidepressants Placebo Response rate 61% 50% Bridge JA, JAMA 2007:297:
17 Maintenance Treatment of Adolescent Depression Maintained response no recurrence Sertraline 38% Placebo 0 52 weeks Cheung et al J Child and Adolescent Psychopharmacology 2008:18:
18 Treatment Algorithm SSRI Different SSRI Different SSRI + CBT Switch to Venlafaxine Switch to Venlafaxine + CBT
19 Other non SSRI Antidepressants Venlafaxine (studied in TORDIA study) Bupropion (no controlled trials for pediatric depression) Selegeline Duloxetine Desvenlafaxine
20 Dosage Range SSRI Fluoxetine: mg Escitalopram: 5-20 mg Sertraline: mg (daily or divided in two dosages) Paroxetine: mg Fluvoxamine: mg Citalopram : mg Non-SSRI Venlafaxine: (both in immediate and XR form) 25 mg to 225 mg can go up to 300 mg Duloxetine: mg Buproprion: mg (additional advantage in comorbid ADHD and less sexual side effects)
21 Newer Antidepressants No efficacy data available in pediatric depression Vilazodone L-Methylfolate Ketamine Levomilancipran Vortioxetine
22 Augmentation to SSRI for Treatment Resistant Depression Atypical antipsychotics - Case series of 10 adolescents with SSRI Resistant Depression, 70% responded to augmentation with Quetiapine - Antidepressants - Buproprion, Mirtazapine - Mood stabilizer - Lithium Pathak S et al J Child and Adolescent Psychopharmacology 2005:15:
23 Do Antidepressants increase the Suicide Risk? Meta Analysis of Pediatric Major depression Antidepressants 3% Placebo 2% Bridge et al, JAMA 2007:297:
24 Alternative Treatments for Pediatric Depression Omega-3 fatty acids Vitamin D supplementation Adjunctive Vitamin C ECT (no controlled data) Repetitive TMS Bright light treatment Exercise
25 Psychological Treatments Different Psychotherapies Family-Based Interpersonal Psychotherapy CBT (Cognitive Behavioral Therapy)
26 Anxiety Disorders DSM V Separation anxiety disorder Selective mutism Specific phobia Generalized anxiety disorder Social anxiety disorder Panic disorder Agoraphobia Anxiety disorder associated with another medical condition Substance-induced anxiety disorder Unspecified anxiety disorder Other specified anxiety disorder
27 Ages of Onset of Risk Autism Spectrum disorder ADHD Anxiety Disorders Depression Bipolar disorder 0-3 years or late for Mild 4-7 years or late for mild 6-12 years 13 years and older >16 years
28 Different terms use for Anxiety Home sickness Worry warts Self conscious or shy Excessive interpersonal sensitivity Fear Apprehension Dread Worry
29 Characteristics Common to all Anxiety Disorders Hyper vigilant Reactive to novel stimuli Threat bias Avoidance coping Catastrophic reactions Parental accommodation Midline physical symptoms
30 Scales for Anxiety Broader scales with anxiety subscales Child Behavioral Checklist(CBCL) Behavioral Assessment System for Children (BASC) Multidimensional Anxiety Scale for Children (MASC) Screen for Child Anxiety Related Disorders (SCARED) Child Version & Parent Version
31 Epidemiology of Anxiety Very common disorder 8-10% Under diagnosed Undertreated Need to look for it
32 Treatment of Pediatric Anxiety Disorders Psychotherapy should be considered as part of treatment of Childhood Anxiety Disorders. Exposure based CBT has the most empirical support. 5 CBT Components: Psycho education Somatic management skills training Cognitive reconstructuring (challenging negative expectations & modifying negative self talk) Exposure methods (exposure with desensitization) Relapse prevention plans (booster sessions)
33 CBT Informed consent of pharmacotherapy is not informed with out a discussion of CBT. CBT is also the first line of treatment for mild to moderate OCD
34 Met analysis of non OCD anxiety RCT Randomized placebo controlled trials of antidepressant in youth; 6 trials ; N = 1136 Generalized anxiety disorder Sertraline to 50 mg (Rynn et al 2001) Venlafaxine to 225 mg (Rynn et al 2007) Social anxiety disorder Paroxetine to 50 mg (Wagner et al 2004) Venlafaxine to 225 mg (March et al) Social Phobia/Separation/ Generalized Anxiety disorder Fluvoxamine to 300 mg (Rupp 2001) Fluoxetine to 20 mg (Birhamer et al 2000)
35 Common side effects: GI: N/V, anorexia, drymouth, dyspepsia CNS: headache, anxiety, nervousness, agitation, insomnia, nocturnal myoclonus, tremor Sexual: anorgasmia,decreased libido, erectile difficulties in males, abnormal ejaculation in males General side effects: SSRI Side Effects asthenia, increased sweating, weightloss Uncommon and potentially serious side effects: Suicidality, hyponatremia, mania/hypomania
36 Guide for Pediatric Anxiety Disorders First Line SSRI,Venlafaxine, Duloxetine Second Line Buspirone, Benzodiazepines, TCA Third Line Mirtazapine, Gaba-ergic anticonvulsants, Propanolol, alpha agonists. Fourth Line- low dose Atypicals, Quetiapine
37 Outcome in Pediatric Anxiety Disorders Retrospective studies suggest that untreated anxiety disorders are persistent (Biederman,1997) 12 prospective studies found that have a childhood anxiety disorder increased risk of developing anxiety disorders in later childhood, adolescence, or adulthood (Costello 2003) Fluvoxamine & Fluoxetine have shown long term efficacy
38 Conclusion Depression is very disabling, prevalent and recurrent disease in adolescents Antidepressants are much more effective in preventing relapses CBT is the first line of treatment for mild to moderate anxiety in children and adolescents
39
#CHAIR2016. September 16 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 16 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Depression in Children and Adolescents Karen Dineen Wagner, MD, PhD University of Texas Medical Branch Galveston, TX Karen Dineen
More informationJuvenile Depression.
Juvenile Depression Karen Dineen Wagner, MD, PhD Titus Harris Chair Professor and Chair Department of Psychiatry & Behavioral Sciences University of Texas Medical Branch Galveston, Texas Disclosure (Past
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationfor anxious and avoidant behaviors.
Summary of the Literature on the Treatment of Anxiety Disorders in Children and Adolescents Sucheta D. Connolly, M.D.* Non-OCD anxiety disorders in youth are common and disabling, with 12-month prevalence
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationManagement Of Depression And Anxiety
Management Of Depression And Anxiety CME Financial Disclosure Statement I, or an immediate family member including spouse/partner, have at present and/or have had within the last 12 months, or anticipate
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More information2/23/18. Age of Anxiety: Transforming Qualms into Calm. Disclosures. Objectives. I have nothing to disclose
Age of Anxiety: Transforming Qualms into Calm Rosa Kim, MD Assistant Professor and Attending Child Psychiatrist Medical College of Wisconsin and Children s Hospital of Wisconsin Disclosures I have nothing
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationFamily Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University
APPROACH TO DEPRESSION IN PRIMARY CARE Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University DISCLOSURE Speaker/Presenter Disclosure
More informationResistance is not futile: working with refractory depression and anxiety
Resistance is not futile: working with refractory depression and anxiety Divulgation des conflits d intérêts Conseil consultatif ou comité analogue Essais cliniques ou études Honoraires ou autres revenus
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationTreatment-resistant depression in primary care
Treatment-resistant depression in primary care Interprofessional CME, October 2017 Brian J. Mickey, MD, PhD Associate Professor School of Medicine Department of Psychiatry Disclosures Speakers bureau:
More informationPediatrics Grand Rounds 5 March University of Texas Health Science Center at San Antonio I-1
Diagnosis and Treatment of Depression in Children and Adolescents Steven R. Pliszka, M.D. Professor and Vice Chair Chief, Division of Child and Adolescent Psychiatry Department of Psychiatry The Disclosures
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationPharmacological Treatment of Anxiety & Depressive Disorders
Pharmacological Treatment of Anxiety & Depressive Disorders Dr Gary Jackson (MB BCh FRCPsych) Consultant Psychiatrist The Priory Hospital Chelmsford Wellesley Hospital Southend-on-Sea Medical Secretary:
More informationSome newer, investigational approaches to treating refractory major depression are being used.
CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Depression and Anxiety Disorders Mood and anxiety disorders are common, and the mortality risk is due primarily to suicide, cardiovascular
More informationChild & Adolescent Psychiatry (a brief overview)
Child & Adolescent Psychiatry (a brief overview) Lance Feldman, MD, FAPA, MBA, BSN Vice Chair Clinical Affairs, Department of Psychiatry Affiliate Clinical Assistant Professor, University of South Carolina
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationPanic disorder is a chronic and recurrent illness associated
CLINICAL PRACTICE GUIDELINES Management of Anxiety Disorders. Panic Disorder, With or Without Agoraphobia Epidemiology Panic disorder is a chronic and recurrent illness associated with significant functional
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationDIAGNOSTIC CRITERIA (ICD 10)
DEPRESSION Depression is a major public health problem around the world Affects 1:5 older people living in the community Affects 2:5 older people living in care homes Various treatment options available,
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationAn Overview of Anxiety and Mood Disorders in Youth
An Overview of Anxiety and Mood Disorders in Youth Mary Kay Nixon MD FRCPC Clinical Associate Professor, UBC Affliliate Associate Professor, UVic Family Physicians Conference February 22, 2012 Victoria,
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More informationDisclosures. Learning Objectives. Psychopharmacology of Pediatric Anxiety and Depression 5/4/2017
Psychopharmacology of Pediatric Anxiety and Depression Susan Sharp, DO Clinical Assistant Professor of Child and Adolescent Psychiatry Kansas University Medical Center The Children's Mercy Hospital, 2017
More informationConsultant Pharmacist Approach to Major Depressive Disorder
Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Objectives What is Depression? Discuss the epidemiology of depression
More informationConsultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO
Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Objectives What is Depression? Discuss the epidemiology of depression
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Medicine: Update 2010 Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California, San Francisco
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationOverview. Part II: Part I: Screening for Depression and Anxiety Risk Assessment Diagnosis of Depressive Disorders
1 Learning Objectives 1. Providers will become familiar with methods of screening for depression and anxiety. 2. Providers will become more comfortable with diagnosis and management of these common pediatric
More informationTreating Childhood Depression in Pediatrics. Martha U. Barnard, Ph.D. University of Kansas Medical Center Pediatrics/Behavioral Sciences
Treating Childhood Depression in Pediatrics Martha U. Barnard, Ph.D. University of Kansas Medical Center Pediatrics/Behavioral Sciences Objectives The learner will: Describe the signs and symptoms of childhood
More informationFROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY
13 th Pearl Leibovitch Clinical Day November 18th, 2014 Mounir H. Samy, MD, FRCP(C) Associate Professor of Psychiatry McGill University (ret.) FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD
More informationIlluminating the Black Box: Antidepressants, Youth and Suicide
Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Postgraduate Medical Education Director, Child and Adolescent Psychiatry
More informationRealities of Depression in Primary Care Setting
Realities of Depression in Primary Care Setting Jaroslava Salman, MD Department of Supportive Care Medicine Division of Psychiatry Click to edit Master Presentation Date August 4 th 2018 Disclosure I have
More informationClinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant
The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island
More informationDepression & Suicide 7/11/2017 DISCLOSURES. DSM 5 Depressive Disorders. Objectives
DISCLOSURES Depression & Suicide July 19, 2017 GenaLynne C. Mooneyham, MD, MS Pediatrics/Psychiatry/Child & Adolescent Psychiatry No financial disclosures There may be discussion of off label medication
More informationAssessing and Treating Depression and Anxiety in Children with Cancer Anna (Nina) Muriel, MD, MPH
Assessing and Treating Depression and Anxiety in Children with Cancer Anna (Nina) Muriel, MD, MPH Chief, Division of Pediatric Psychosocial Oncology Department of Psychosocial Oncology and Palliative Care
More informationJoel V. Oberstar, M.D. 1
Diagnosis and Treatment of Depressive Disorders in Children and Adolescents Joel V. Oberstar, M.D. CEO & Chief Medical Officer Adjunct Assistant Professor of Psychiatry University of Minnesota Medical
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationDEPRESSION Depression is a major public health problem around the world Affects 1:5 older people living in the community Affects 2:5 older people living in care homes Various treatment options available,
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationBrief Notes on the Mental Health of Children and Adolescents
Brief Notes on the Mental Health of Children and Adolescents The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems
More informationDaniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School
Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical
More information48 th Annual Meeting. Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5. Disclosure. Depression. Patient Case. Objectives 7/19/2014
48 th Annual Meeting Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5 Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Published in 2013 Most published treatment guidelines
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationModerate depression, low/moderate safety risk, age < 12
Depressive Disorders Patterns of excessive depressed or irritable moods, with associated neurovegetative symptoms (sleep, appetite, concentration), guilty feelings, suicidality, guilt, and functional impairment
More informationWhen The Kids Aren t Alright
When The Kids Aren t Alright Evaluation and treatment strategies for childhood anxiety and depression in primary care Megan Chiarelli, MD Child & Adolescent Psychiatry, General Psychiatry Medical Director
More informationTreatment of Depression in the Primary Care Office
Treatment of Depression in the Primary Care Office Paul E.A. Glaser, MD, PhD Departments of Psychiatry, Pediatrics and Anatomy & Neurobiology University of Kentucky November 5, 2010 Disclosures of Potential
More informationAdolescent depression
Diagnostic skills can differentiate 40 VOL. 1, NO. 7 / JULY 2002 teen angst from psychopathology Ann Wagner, PhD Chief, Autism and Pervasive Developmental Disorders Intervention Research Program Benedetto
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationStart Low, Go Slow but Treat to Target
Start Low, Go Slow but Treat to Target Pharmacotherapy for Depression, Anxiety and At-Risk Alcohol Use in Late Life September 29, 2014 Audio and Control Panel instruction On the phone? Raise your hand
More informationANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN
UW PACC Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL
More informationObsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care
Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,
More informationPEDIATRIC DEPRESSION AND ANXIETY
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences PEDIATRIC DEPRESSION AND ANXIETY CECILIA MARGRET MD UNIVERSITY OF WASHINGTON GENERAL DISCLOSURES The University
More informationMore Than Just Moody Blaise Aguirre, MD Child and Adolescent Psychiatrist McLean Hospital Assistant Professor of Psychiatry Harvard Medical School
More Than Just Moody Blaise Aguirre, MD Child and Adolescent Psychiatrist McLean Hospital Assistant Professor of Psychiatry Harvard Medical School Keep in Mind In the U.S., approximately 10-15% of children/adolescents
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX
A acceptance and commitment therapy Posttraumatic Stress, 69 ADHD Adjunctive Fatty Acids, 5 Adjunctive Guanfacine Pharmacokinetics, 27 Amantadine, 21 Atomoxetine, 23 Cancer Risk, 31 CBT for Comorbid Anxiety,
More informationDepression in the Medically Ill
Mayo School of Continuous Professional Development Psychiatry in Medical Settings February 9 th, 2017 Depression in the Medically Ill David Katzelnick, M.D. Professor of Psychiatry, Mayo Clinic College
More informationManaging Late Life Depression
Managing Late Life Depression Maria I. Lapid, M.D, Professor of Psychiatry Program Director, Geriatric Psychiatry Fellowship Simon Kung, M.D. Associate Professor of Psychiatry Medical Director, Mood Disorders
More informationTreatment of Anxiety and Mood Disorders. John T. Walkup, MD Division of Child and Adolescent Psychiatry Weill Cornell Medical College New York, NY
Treatment of Anxiety and Mood Disorders John T. Walkup, MD Division of Child and Adolescent Psychiatry Weill Cornell Medical College New York, NY Disclosure: John T. Walkup, MD Consultant Advisory Board
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Age as factor in selective mutism, 623 as factor in social phobia, 623 Agoraphobia, 593 600 described, 594 596 DSM-V changes related to,
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationDisclosures. Questions. A Developmental Approach. Goals and objectives 4/3/2018 FEARS AND TEARS: TREATING ANXIETY AND DEPRESSION IN PRIMARY CARE
Disclosures FEARS AND TEARS: TREATING ANXIETY AND DEPRESSION IN PRIMARY CARE I have no financial interests I WILL be talking about non FDA approved uses of medications for anxiety and depression in children
More informationDepression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms
Depression and Anxiety By Christopher Okiishi, MD Spring 2016 What is Depression? Not just being sad A syndrome of symptoms Depressed mood Sleep disturbance Decreased interest in usual activities (anhedonia)
More informationReviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More informationDepression Workshop 26 January 2007
Depression Workshop 26 January 2007 Leslie G Walker Professor of Cancer Rehabilitation Donald M Sharp Senior Lecturer in Behavioural Oncology Mary B Walker Senior Clinical and Research Nurse Specialist
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationDisclosures - None. Learning Objectives. Emerging Issues Prevalence of Mood Disorders. Update on Depression-2012
Disclosures - None Update on Depression-2012 Russell G. Vasile, M. D. Associate Professor of Psychiatry Beth Israel Deaconess Medical Center Harvard Medical School Learning Objectives Understand the spectrum
More informationcontrols past MDD current MDD
인제대학교서울백병원김원 * decreased appetite * decreased sleep * psychomotor agitaion * poor concentraion * psychomotor retardation * anhedonia depressed mood * low energy * guilt suicidal ideation * < 0.05 * total
More informationDepression in Adolescents PREMA MANJUNATH, MD CHILD AND ADOLESCENT PSYCHIATRIST
Depression in Adolescents PREMA MANJUNATH, MD CHILD AND ADOLESCENT PSYCHIATRIST Francis Bacon Children sweeten labors, but they make misfortunes bitter. They increase the cares of life, but they mitigate
More informationMajor Depression and Anxiety in Adolescents and Adults
Major Depression and Anxiety in Adolescents and Adults Miggie Greenberg, M.D. Associate Professor of Psychiatry St. Louis University School of Medicine greenbml@slu.edu *NO DISCLOSURES* OBJECTIVES * Recognize
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationMood Disorders-Major Depression
Mood Disorders Paula Gibbs, MD Assistant Professor Department of Psychiatry Medical Director of 5West Med-Psych University of Utah Hospitals and Clinics Mood Disorders-Major Depression Key Points for Major
More informationKessler 1994; Kessler 1995; DSM-IV-TR 2000.
Fast and Effective Treatment of Anxiety and Depression in the Primary Care Office Paul E.A. Glaser MD, PhD Departments of Psychiatry, Pediatrics, and Anatomy & Neurobiology April 9, 2010 Disclosure Information
More informationTreatment of Major Depressive Disorder
Treatment of Major Depressive Disorder Sarah Mullowney, MD PGY3 Psychiatry Resident, University of Utah Paula Gibbs, MD Medical Director of 5 West at UUMC Clerkship Director MS III Psychiatric Rotation
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationMedication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG
Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine
More informationMental Health Practice Support
Initial Screening and Triage for Follow-up HEALTH TEAM Depression is suspected: Perform two-question screen 1,2 (box 1)* Review risk factors 1-3 (box 2) Diagnose and characterize MDE with clinical interview:
More informationStrategies for Diagnosing and Treating Depressive Disorders in Primary Care
Strategies for Diagnosing and Treating Depressive Disorders in Primary Care David Katerndahl, MD, MA University of Texas Health Science Center San Antonio, Texas Speaker Disclosure Dr. Katerndahl has disclosed
More information2013 Virtual AD/HD Conference 1
Medication for & Coexisting Conditions Part 2 Dr. Kenny Handelman Child, Adolescent & Adult Psychiatrist Halton Healthcare Adjunct Professor of Psychiatry, University of Western Ontario www.drkenny.com
More informationDepression major depressive disorder. Some terms: Major Depressive Disorder: Major Depressive Disorder:
Depression major depressive disorder Oldest recognized disorder: melancholia It is a positive and active anguish, a sort of psychical neuralgia wholly unknown to normal life. - William James "I am now
More informationAnnouncements. The final Aplia gauntlet: Final Exam is May 14, 3:30 pm Still more experiments going up daily! Enhanced Grade-query Tool+
The final Aplia gauntlet: Announcements Chapter 12 Aplia due tonight Chapter 13 Aplia due Wednesday Final Exam is May 14, 3:30 pm Still more experiments going up daily! Enhanced Grade-query Tool+ Now includes
More informationFor: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013
For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013 This power point is only a guideline for recommendations in the treatment of psychiatric disorders. This is not comprehensive. Please
More informationPediatric Depression and Anxiety. Cecilia Margret, MD PhD MPH PAL Conference
Pediatric Depression and Anxiety Cecilia Margret, MD PhD MPH PAL Conference I have no relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider of commercial
More information